Armand Bensussan

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2590499/publications.pdf

Version: 2024-02-01

234 papers	10,152 citations	41627 51 h-index	53065 89 g-index
268 all docs	268 docs citations	268 times ranked	12416 citing authors

#	Article	IF	Citations
1	Involvement of the CD39/CD73/adenosine pathway in T-cell proliferation and NK cell-mediated antibody-dependent cell cytotoxicity in SÃ©zary syndrome. Blood, 2022, 139, 2712-2716.	0.6	14
2	CCR8 is a new therapeutic target in cutaneous T-cell lymphomas. Blood Advances, 2022, 6, 3507-3512.	2.5	6
3	The soluble form of CD160 acts as a tumor mediator of immune escape in melanoma. Cancer Immunology, Immunotherapy, 2022, 71, 2731-2742.	2.0	6
4	Bi38-3 is a novel CD38/CD3 bispecific T-cell engager with low toxicity for the treatment of multiple myeloma. Haematologica, 2021, 106, 1193-1197.	1.7	23
5	The value of five blood markers in differentiating mycosis fungoides and SÃ©zary syndrome: a validation cohort. British Journal of Dermatology, 2021, 185, 405-411.	1.4	7
6	Expansion of Circulating CD49b+LAG3+ Type 1 Regulatory T Cells in Human Chronic Graft-Versus-Host Disease. Journal of Investigative Dermatology, 2021, 141, 193-197.e2.	0.3	4
7	PAK1-Dependent Antitumor Effect of AAC-11â€'Derived Peptides on SÃ©zary Syndrome Malignant CD4+ T Lymphocytes. Journal of Investigative Dermatology, 2021, 141, 2261-2271.e5.	0.3	3
8	Secretomic and proteomic analysis of cutaneous T cell lymphoma-associated fibroblasts. European Journal of Cancer, 2021, 156, S5.	1.3	0
9	Exploring the role of the skin microenvironment in cutaneous T-cell lymphoma using single cell RNA-sequencing. European Journal of Cancer, 2021, 156, S3-S4.	1.3	3
10	ICOS is widely expressed in cutaneous T-cell lymphoma and its targeting promotes potent killing of malignant cells. European Journal of Cancer, 2021, 156, S23-S24.	1.3	1
11	Anti-tumor effect of anti-apoptosis clone 11 protein-derived peptides on SÃ©zary syndrome malignant CD4+ T lymphocytes. European Journal of Cancer, 2021, 156, S14.	1.3	0
12	Quantifying response to various treatments using the revisited blood staging of mycosis fungoides and SÃ©zary syndrome with the KIR3DL2 marker. European Journal of Cancer, 2021, 156, S6-S7.	1.3	0
13	ICOS Is Widely Expressed in Cutaneous T-Cell Lymphoma and Its Targeting Promotes Potent Killing of Malignant Cells. Blood, 2021, 138, 790-790.	0.6	4
14	Chimerized Anti-ICOS 314.8 Monoclonal Antibodies Inhibit Tumor Cells and Regulatory T Cells in Patients with SÃ©zary Syndrome. Blood, 2021, 138, 2260-2260.	0.6	0
15	857â€...Selective Treg depletion in solid tumors with ALD2510, a novel humanized CD25-specific, IL-2 sparing monoclonal antibody. , 2021, 9, A898-A898.		3
16	Revisiting the initial diagnosis and blood staging of mycosis fungoides and SÃ©zary syndrome with the <scp>KIR</scp> 3 <scp>DL</scp> 2 marker. British Journal of Dermatology, 2020, 182, 1415-1422.	1.4	20
17	Persistent deficiency of mucosal-associated invariant T cells during dermatomyositis. Rheumatology, 2020, 59, 2282-2286.	0.9	19
18	ICOS is widely expressed in cutaneous T-cell lymphoma, and its targeting promotes potent killing of malignant cells. Blood Advances, 2020, 4, 5203-5214.	2.5	18

#	Article	IF	Citations
19	MDA5+ Dermatomyositis Is Associated with Stronger Skin Type I Interferon Transcriptomic Signature with Upregulation of IFN-Î² Transcript. Journal of Investigative Dermatology, 2020, 140, 1276-1279.e7.	0.3	30
20	In vivo anti-MUC1+ tumor activity and sequences of high-affinity anti-MUC1-SEA antibodies. Cancer Immunology, Immunotherapy, 2020, 69, 1337-1352.	2.0	15
21	Effect of expression of ICOS in cutaneous T-cell lymphoma and its targeting on killing of malignant cells.. Journal of Clinical Oncology, 2020, 38, e20040-e20040.	0.8	2
22	Atypical BRAF and NRAS Mutations in Mucosal Melanoma. Cancers, 2019, 11, 1133.	1.7	47
23	Cutaneous T-cell lymphoma cells release proapoptotic Fas ligand in lysosomal secretory vesicles. European Journal of Cancer, 2019, 119, S17.	1.3	0
24	671 Study of the molecular and functional effects of wound dressings on human dermal fibroblasts. Journal of Investigative Dermatology, 2019, 139, S330.	0.3	0
25	Identification of CD39 as a Marker for the Circulating Malignant T-Cell Clone of SÃ©zary Syndrome Patients. Journal of Investigative Dermatology, 2019, 139, 725-728.	0.3	6
26	IPH4102, a first-in-class anti-KIR3DL2 monoclonal antibody, in patients with relapsed or refractory cutaneous T-cell lymphoma: an international, first-in-human, open-label, phase 1 trial. Lancet Oncology, The, 2019, 20, 1160-1170.	5.1	119
27	Blocking Antibodies Targeting the CD39/CD73 Immunosuppressive Pathway Unleash Immune Responses in Combination Cancer Therapies. Cell Reports, 2019, 27, 2411-2425.e9.	2.9	274
28	Microenvironment tailors nTreg structure and function. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 6298-6307.	3.3	22
29	Extracellular Vesicles Released by Allogeneic Human Cardiac Stem/Progenitor Cells as Part of Their Therapeutic Benefit. Stem Cells Translational Medicine, 2019, 8, 911-924.	1.6	12
30	Soluble Fc-Disabled Herpes Virus Entry Mediator Augments Activation and Cytotoxicity of NK Cells by Promoting Cross-Talk between NK Cells and Monocytes. Journal of Immunology, 2019, 202, 2057-2068.	0.4	0
31	664 Biological activities of traditional medicinal herbs on skin cells. Journal of Investigative Dermatology, 2019, 139, S329.	0.3	0
32	Increased CD8+CD28- circulating T cells and high blood interferon score characterize the systemic inflammation of amyopathic dermatomyositis. Journal of the American Academy of Dermatology, 2019, 85, 755-758.	0.6	1
33	Increased expression of <scp>PD</scp>1 and <scp>CD</scp>39 on <scp>CD</scp>3⁺<scp>CD</scp>4⁺ skin T cells in the elderly. Experimental Dermatology, 2019, 28, 80-82.	1.4	10
34	Truncating mutations of TP53AIP1 gene predispose to cutaneous melanoma. Genes Chromosomes and Cancer, 2018, 57, 294-303.	1.5	8
35	Cutaneous presentation of adult T-cell leukemia/lymphoma (ATLL). Single-center study on 37 patients in metropolitan France between 1996 and 2016. Annales De Dermatologie Et De Venereologie, 2018, 145, 405-412.	0.5	10
36	Impact of prednisone in patients with repeated embryo implantation failures: Beneficial or deleterious?. Journal of Reproductive Immunology, 2018, 127, 11-15.	0.8	36

#	Article	IF	Citations
37	The Interleukin-17 Family of Cytokines in Breast Cancer. International Journal of Molecular Sciences, 2018, 19, 3880.	1.8	50
38	Cytokine levels in persistent skin lesions of adult-onset Still disease. Journal of the American Academy of Dermatology, 2018, 79, 947-949.	0.6	8
39	Revisiting blood classification in Mycosis Fungoides and SÃ©zary syndrome with the KIR3DL2 marker. European Journal of Cancer, 2018, 101, S10-S11.	1.3	0
40	KIR3DL2 expression in patients with adult T-cell lymphoma/leukaemia (ATLL). European Journal of Cancer, 2018, 101, S7-S8.	1.3	0
41	Anti-CD160, Alone or in Combination With Bevacizumab, Is a Potent Inhibitor of Ocular Neovascularization in Rabbit and Monkey Models. , 2018, 59, 2687.		7
42	Triple-negative and HER2-overexpressing breast cancer cell sialylation impacts tumor microenvironment T-lymphocyte subset recruitment: a possible mechanism of tumor escape. Cancer Management and Research, 2018, Volume 10, 1051-1059.	0.9	8
43	CD160 Expression in Retinal Vessels Is Associated With Retinal Neovascular Diseases. , 2018, 59, 2679.		6
44	Argx-110 for Treatment of CD70-Positive Advanced Cutaneous T-Cell Lymphoma in a Phase 1/2 Clinical Trial. Blood, 2018, 132, 1627-1627.	0.6	6
45	CD160. , 2018, , 846-852.		0
46	PDE4D promotes FAK-mediated cell invasion in BRAF-mutated melanoma. Oncogene, 2017, 36, 3252-3262.	2.6	25
47	Minimizing the risk of allo-sensitization to optimize the benefit of allogeneic cardiac-derived stem/progenitor cells. Scientific Reports, 2017, 7, 41125.	1.6	14
48	Usefulness of KIR3DL2 to Diagnose, Follow-Up, and Manage the Treatment of Patients with SÃ©zary Syndrome. Clinical Cancer Research, 2017, 23, 3619-3627.	3.2	41
49	Study of gene expression alteration in male androgenetic alopecia: evidence of predominant molecular signalling pathways. British Journal of Dermatology, 2017, 177, 1322-1336.	1.4	44
50	KIR3DL2 expression in cutaneous T-cell lymphomas: expanding the spectrum for KIR3DL2 targeting. Blood, 2017, 130, 2900-2902.	0.6	30
51	Chemotherapy treatment induces an increase of autophagy in the luminal breast cancer cell MCF7, but not in the triple-negative MDA-MB231. Scientific Reports, 2017, 7, 7201.	1.6	39
52	Phase I Study of IPH4102, Anti-KIR3DL2 Mab, in Relapsed/Refractory Cutaneous T-Cell Lymphomas (CTCL): Dose-escalation Safety, Biomarker and Clinical Activity Results. Hematological Oncology, 2017, 35, 48-49.	0.8	8
53	Circulating and skin-derived SÃ©zary cells: clonal but with phenotypic plasticity. Blood, 2017, 130, 1468-1471.	0.6	44
54	Dermatopulmonary Syndrome Associated With Anti-MDA5 Antibodies After Allogeneic Hematopoietic Stem Cell Transplantation. JAMA Dermatology, 2017, 153, 184.	2.0	17

#	Article	IF	Citations
55	Uterine immune profiling for increasing live birth rate: A one-to-one matched cohort study. Journal of Reproductive Immunology, 2017, 119, 23-30.	0.8	47
56	Therapeutic Antibodies to KIR3DL2 and Other Target Antigens on Cutaneous T-Cell Lymphomas. Frontiers in Immunology, 2017, 8, 1010.	2.2	18
57	Human Cardiac-Derived Stem/Progenitor Cells Fine-Tune Monocyte-Derived Descendants Activities toward Cardiac Repair. Frontiers in Immunology, 2017, 8, 1413.	2.2	12
58	Up-and-down immunity of pregnancy in humans. F1000Research, 2017, 6, 1216.	0.8	36
59	The IL-17B-IL-17 receptor B pathway promotes resistance to paclitaxel in breast tumors through activation of the ERK1/2 pathway. Oncotarget, 2017, 8, 113360-113372.	0.8	33
60	Interleukin 17 in the tumor microenvironment: A potent target for anticancer immunotherapy?. Journal of Clinical Oncology, 2017, 35, 115-115.	0.8	1
61	Abstract 1602: Generation of anti-IL-17B antibodies neutralizing IL-17B-mediated alterations of the immune microenvironment, promotion of tumor cell initiating capacity and chemoresistance. , 2017, , .		0
62	TERT promoter mutations in melanoma render TERT expression dependent on MAPK pathway activation. Oncotarget, 2016, 7, 53127-53136.	0.8	54
63	Targeting the Tumor Microenvironment: The Protumor Effects of IL-17 Related to Cancer Type. International Journal of Molecular Sciences, 2016, 17, 1433.	1.8	104
64	Evaluation of Immunophenotypic and Molecular Biomarkers for SÃ©zary Syndrome Using Standard Operating Procedures: A Multicenter Study of 59 Patients. Journal of Investigative Dermatology, 2016, 136, 1364-1372.	0.3	78
65	Evidence of <scp>T</scp>h1, <scp>T</scp>h17 and <scp>T</scp>c17 cells in psoriasiform chronic graftâ€versusâ€host disease. Experimental Dermatology, 2016, 25, 64-65.	1.4	10
66	The Uterine Immune Profile May Help Women With Repeated Unexplained Embryo Implantation Failure After In Vitro Fertilization. American Journal of Reproductive Immunology, 2016, 75, 388-401.	1.2	143
67	APRIL levels are associated with disease activity in human chronic graft-versus-host disease. Haematologica, 2016, 101, e312-e315.	1.7	9
68	Phenotypic and functional changes in dermal primary fibroblasts isolated from intrinsically aged human skin. Experimental Dermatology, 2016, 25, 113-119.	1.4	46
69	Intrinsically aged dermal fibroblasts fail to differentiate into adipogenic lineage. Experimental Dermatology, 2016, 25, 906-909.	1.4	1
70	Expression of SÃ©zary Biomarkers in the Blood of Patients with Erythrodermic Mycosis Fungoides. Journal of Investigative Dermatology, 2016, 136, 317-320.	0.3	16
71	Tremâ€1 is not crucial in psoriasiform imiquimodâ€induced skin inflammation in mice. Experimental Dermatology, 2016, 25, 400-402.	1.4	6
72	PARKINInactivation Links Parkinsonâ€™s Disease to Melanoma. Journal of the National Cancer Institute, 2016, 108, djv340.	3.0	56

#	Article	IF	Citations
73	CD160. , 2016, , 1-7.		2
74	First-in-Human, Multicenter Phase I Study of IPH4102, First-in-Class Humanized Anti-KIR3DL2 Monoclonal Antibody, in Relapsed/Refractory Cutaneous T-Cell Lymphomas: Preliminary Safety, Exploratory and Clinical Activity Results. Blood, 2016, 128, 1826-1826.	0.6	6
75	MUC1-ARFâ€"A Novel MUC1 Protein That Resides in the Nucleus and Is Expressed by Alternate Reading Frame Translation of MUC1 mRNA. PLoS ONE, 2016, 11, e0165031.	1.1	11
76	IL-17E synergizes with EGF and confers in vitro resistance to EGFR-targeted therapies in TNBC cells. Oncotarget, 2016, 7, 53350-53361.	0.8	23
77	RICTOR involvement in the PI3K/AKT pathway regulation in melanocytes and melanoma. Oncotarget, 2015, 6, 28120-28131.	0.8	26
78	CD39: A complementary target to immune checkpoints to counteract tumor-mediated immunosuppression. OncoImmunology, 2015, 4, e1003015.	2.1	33
79	Inhibition of CD39 Enzymatic Function at the Surface of Tumor Cells Alleviates Their Immunosuppressive Activity. Cancer Immunology Research, 2015, 3, 254-265.	1.6	190
80	KIR3DL2/CpG ODN Interaction Mediates SÃ©zary Syndrome Malignant T Cell Apoptosis. Journal of Investigative Dermatology, 2015, 135, 229-237.	0.3	14
81	IL-17A and its homologs IL-25/IL-17E recruit the c-RAF/S6 kinase pathway and the generation of pro-oncogenic LMW-E in breast cancer cells. Scientific Reports, 2015, 5, 11874.	1.6	45
82	Deficient regulatory B cells in human chronic graft-versus-host disease. OncoImmunology, 2015, 4, e1016707.	2.1	11
83	Authors' Reply. American Journal of Pathology, 2015, 185, 1168.	1.9	1
84	CD24hiCD27+ and plasmablast-like regulatory B cells in human chronic graft-versus-host disease. Blood, 2015, 125, 1830-1839.	0.6	144
85	Colony Stimulating Factors 1, 2, 3 and early pregnancy steps: from bench to bedside. Journal of Reproductive Immunology, 2015, 109, 1-6.	0.8	33
86	A novel targeted immunotherapy for CTCL is on its way: Anti-KIR3DL2 mAb IPH4102 is potent and safe in non-clinical studies. OncoImmunology, 2015, 4, e1022306.	2.1	21
87	CD Nomenclature 2015: Human Leukocyte Differentiation Antigen Workshops as a Driving Force in Immunology. Journal of Immunology, 2015, 195, 4555-4563.	0.4	125
88	Genes involved in the <scp>WNT</scp> and vesicular trafficking pathways are associated with melanoma predisposition. International Journal of Cancer, 2015, 136, 2109-2119.	2.3	27
89	CD158k Is a Reliable Marker for Diagnosis of SÃ©zary Syndrome and Reveals an Unprecedented Heterogeneity of Circulating Malignant Cells. Journal of Investigative Dermatology, 2015, 135, 247-257.	0.3	56
90	Autophagy is decreased in triple-negative breast carcinoma involving likely the MUC1-EGFR-NEU1 signalling pathway. International Journal of Clinical and Experimental Pathology, 2015, 8, 4344-55.	0.5	8

#	Article	IF	Citations
91	T-Plastin Expression Downstream to the Calcineurin/NFAT Pathway Is Involved in Keratinocyte Migration. PLoS ONE, 2014, 9, e104700.	1.1	15
92	IPH4102, a Humanized KIR3DL2 Antibody with Potent Activity against Cutaneous T-cell Lymphoma. Cancer Research, 2014, 74, 6060-6070.	0.4	65
93	NKp46-Specific Expression on Skin-Resident CD4 + Lymphocytes in Mycosis Fungoides and SÃ©zary Syndrome. Journal of Investigative Dermatology, 2014, 134, 574-578.	0.3	3
94	A Large French Case-Control Study Emphasizes the Role of RareMc1RVariants in Melanoma Risk. BioMed Research International, 2014, 2014, 1-10.	0.9	19
95	Contribution of <scp>CD</scp>39 to the immunosuppressive microenvironment of acute myeloid leukaemia at diagnosis. British Journal of Haematology, 2014, 165, 722-725.	1.2	26
96	Membrane expression of NK receptors CD160 and CD158k contributes to delineate a unique CD4⁺ Tâ€lymphocyte subset in normal and mycosis fungoides skin. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2014, 85, 869-882.	1.1	16
97	Regulatory T-Cells in Pregnancy: Historical Perspective, State of the Art, and Burning Questions. Frontiers in Immunology, 2014, 5, 389.	2.2	79
98	Lymphocyte-derived interleukin-17A adds another brick in the wall of inflammation-induced breast carcinogenesis. OncoImmunology, 2014, 3, e28273.	2.1	29
99	HACE1, a Potential Tumor Suppressor Gene on 6q21, Is Not Involved in Extranodal Natural Killer/T-Cell Lymphoma Pathophysiology. American Journal of Pathology, 2014, 184, 2899-2907.	1.9	13
100	KIR3DL2 is a coinhibitory receptor on SÃ©zary syndrome malignant T cells that promotes resistance to activation-induced cell death. Blood, 2014, 124, 3330-3332.	0.6	22
101	Granulocyte-Colony Stimulating Factor Related Pathways Tested on an Endometrial Ex-Vivo Model. PLoS ONE, 2014, 9, e102286.	1.1	53
102	Seminal plasma peptides may determine maternal immune response that alters success or failure of pregnancy in the abortion-prone CBAxDBA/2 model. Journal of Reproductive Immunology, 2013, 99, 46-53.	0.8	28
103	MUC1/CD227 IMMUNOHISTOCHEMISTRY IN ROUTINE PRACTICE IS A USEFUL BIOMARKER IN BREAST CANCERS. Journal of Immunoassay and Immunochemistry, 2013, 34, 232-245.	0.5	2
104	Genetic variation at <scp>KIT</scp> locus may predispose to melanoma. Pigment Cell and Melanoma Research, 2013, 26, 88-96.	1.5	5
105	IL-17A is produced by breast cancer TILs and promotes chemoresistance and proliferation through ERK1/2. Scientific Reports, 2013, 3, 3456.	1.6	119
106	Inducible expression and pathophysiologic functions of T-plastin in cutaneous T-cell lymphoma. Blood, 2012, 120, 143-154.	0.6	33
107	Active and Passive Anticytokine Immune Therapies: Current Status and Development. Advances in Immunology, 2012, 115, 187-227.	1.1	9
108	TWEAK Affects Keratinocyte G2/M Growth Arrest and Induces Apoptosis through the Translocation of the AIF Protein to the Nucleus. PLoS ONE, 2012, 7, e33609.	1.1	41

#	Article	IF	Citations
109	CD158k/KIR3DL2 and NKp46 are frequently expressed in transformed mycosis fungoides. Experimental Dermatology, 2012, 21, 461-463.	1.4	36
110	Active Chronic Sarcoidosis is Characterized by Increased Transitional Blood B Cells, Increased IL-10-Producing Regulatory B Cells and High BAFF Levels. PLoS ONE, 2012, 7, e43588.	1.1	78
111	Assessment of tyrosinase variants and skin cancer risk in a large cohort of French subjects. Journal of Dermatological Science, 2011, 64, 127-133.	1.0	17
112	CD101 Expression and Function in Normal and Rheumatoid Arthritis-affected Human T Cells and Monocytes/Macrophages. Journal of Rheumatology, 2011, 38, 419-428.	1.0	16
113	Engagement of IL-1 receptor accessory protein (IL-1RAcP) with the monoclonal antibody AY19 provides co-activating signals and prolongs the CD2-induced proliferation of peripheral blood lymphocytes. Immunology Letters, 2011, 139, 52-57.	1.1	5
114	Death ligand TRAIL, secreted by CD1a+ and CD14+ cells in blister fluids, is involved in killing keratinocytes in toxic epidermal necrolysis. Experimental Dermatology, 2011, 20, 107-112.	1.4	35
115	ERK and PDE4 cooperate to induce RAF isoform switching in melanoma. Nature Structural and Molecular Biology, 2011, 18, 584-591.	3.6	81
116	Differential and tumor-specific expression of CD160 in B-cell malignancies. Blood, 2011, 118, 2174-2183.	0.6	47
117	CD160: A unique activating NK cell receptor. Immunology Letters, 2011, 138, 93-96.	1.1	81
118	IFN-Î± and CD46 stimulation are associated with active lupus and skew natural T regulatory cell differentiation to type 1 regulatory T (Tr1) cells. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 18995-19000.	3.3	52
119	A novel antiangiogenic and vascular normalization therapy targeted against human CD160 receptor. Journal of Experimental Medicine, 2011, 208, 973-986.	4.2	46
120	Human endothelial cells generate Th17 and regulatory T cells under inflammatory conditions. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 2891-2896.	3.3	107
121	Extranodal NK/T-Cell Lymphoma: Toward the Identification of Clinical Molecular Targets. Journal of Biomedicine and Biotechnology, 2011, 2011, 1-11.	3.0	19
122	CD39/Adenosine Pathway Is Involved in AIDS Progression. PLoS Pathogens, 2011, 7, e1002110.	2.1	154
123	Expression and Function of the Natural Cytotoxicity Receptor NKp46 on Circulating Malignant CD4+ T Lymphocytes of SÃ©zary Syndrome Patients. Journal of Investigative Dermatology, 2011, 131, 969-976.	0.3	41
124	Human and Mouse Mast Cells Express and Secrete the GPI-Anchored Isoform of CD160. Journal of Investigative Dermatology, 2011, 131, 916-924.	0.3	23
125	Two Domains of Vimentin Are Expressed on the Surface of Lymph Node, Bone and Brain Metastatic Prostate Cancer Lines along with the Putative Stem Cell Marker Proteins CD44 and CD133. Cancers, 2011, 3, 2870-2885.	1.7	36
126	Histopathologic Diagnosis of Lymphomatous Versus Inflammatory Erythroderma: A Morphologic and Phenotypic Study on 47 Skin Biopsies. American Journal of Dermatopathology, 2010, 32, 755-763.	0.3	51

#	Article	IF	Citations
127	CD160 signaling mediates PI3K-dependent survival and growth signals in chronic lymphocytic leukemia. Blood, 2010, 115, 3079-3088.	0.6	48
128	A novel KIR-associated function: evidence that CpG DNA uptake and shuttling to early endosomes is mediated by KIR3DL2. Blood, 2010, 116, 1637-1647.	0.6	83
129	ILâ€10 produced by activated human B cells regulates CD4⁺ Tâ€cell activation in vitro. European Journal of Immunology, 2010, 40, 2686-2691.	1.6	216
130	IFNÎ± kinoid vaccine-induced neutralizing antibodies prevent clinical manifestations in a lupus flare murine model. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 5294-5299.	3.3	205
131	Identification and Characterization of a Transmembrane Isoform of CD160 (CD160-TM), a Unique Activating Receptor Selectively Expressed upon Human NK Cell Activation. Journal of Immunology, 2009, 182, 63-71.	0.4	58
132	NKG2D Ligands Expression and NKG2D-Mediated NK Activity in Sezary Patients. Journal of Investigative Dermatology, 2009, 129, 359-364.	0.3	16
133	Regulatory T cells differentially modulate the maturation and apoptosis of human CD8+ T-cell subsets. Blood, 2009, 113, 4556-4565.	0.6	54
134	CD158K/KIR3DL2 Transcript Detection in Lesional Skin of Patients with Erythroderma Is a Tool for the Diagnosis of SÃ©zary Syndrome. Journal of Investigative Dermatology, 2008, 128, 465-472.	0.3	51
135	NK cells and surveillance in humans. Reproductive BioMedicine Online, 2008, 16, 192-201.	1.1	14
136	Critical and Differential Roles of NKp46- and NKp30-Activating Receptors Expressed by Uterine NK Cells in Early Pregnancy. Journal of Immunology, 2008, 181, 3009-3017.	0.4	125
137	Cutting Edge: Selective Expression of Inhibitory or Activating Killer Cell Ig-Like Receptors in Circulating CD4+ T Lymphocytes. Journal of Immunology, 2008, 180, 2767-2771.	0.4	15
138	A Soluble Form of the MHC Class I-Specific CD160 Receptor Is Released from Human Activated NK Lymphocytes and Inhibits Cell-Mediated Cytotoxicity. Journal of Immunology, 2007, 178, 1293-1300.	0.4	51
139	Increased Number of Cytotoxic CD3+CD28â€“ Î³Î´ T Cells in Peripheral Blood of Patients with Cutaneous Malignant Melanoma. Dermatology, 2007, 214, 283-288.	0.9	13
140	VEGF kinoid vaccine, a therapeutic approach against tumor angiogenesis and metastases. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 2837-2842.	3.3	193
141	CD160-activating NK cell effector functions depend on the phosphatidylinositol 3-kinase recruitment. International Immunology, 2007, 19, 401-409.	1.8	42
142	Killer cell Ig-like receptors CD158a and CD158b display a coactivatory function, involving the c-Jun NH2-terminal protein kinase signaling pathway, when expressed on malignant CD4+ T cells from a patient with SÃ©zary syndrome. Blood, 2007, 109, 5064-5065.	0.6	23
143	Control of allergic reactions in mice by an active anti-murine IL-4 immunization. Vaccine, 2007, 25, 7206-7216.	1.7	21
144	Identification of a Novel CD160+CD4+ T-Lymphocyte Subset in the Skin: A Possible Role for CD160 in Skin Inflammation. Journal of Investigative Dermatology, 2007, 127, 1161-1166.	0.3	31

#	Article	IF	Citations
145	Soluble HLA-G and control of angiogenesis. Journal of Reproductive Immunology, 2007, 76, 17-22.	0.8	44
146	Recent discoveries in the genetics of melanoma and their therapeutic implications. Archivum Immunologiae Et Therapiae Experimentalis, 2007, 55, 363-372.	1.0	19
147	Engagement of the CD160 activating NK cell receptor leads to its association with CD2 in circulating human NK cells. Transplant Immunology, 2006, 17, 36-38.	0.6	14
148	Significance of circulating T-cell clones in Sèzary syndrome. Blood, 2006, 107, 4030-4038.	0.6	69
149	Soluble HLA-G1 inhibits angiogenesis through an apoptotic pathway and by direct binding to CD160 receptor expressed by endothelial cells. Blood, 2006, 108, 2608-2615.	0.6	181
150	Heterogeneous Abnormalities of CCND1 and RB1 in Primary Cutaneous T-Cell Lymphomas Suggesting Impaired Cell Cycle Control in Disease Pathogenesis. Journal of Investigative Dermatology, 2006, 126, 1388-1395.	0.3	33
151	Antiproliferative Effect of Semaphorin 3F on Human Melanoma Cell Lines. Journal of Investigative Dermatology, 2006, 126, 2343-2345.	0.3	19
152	The co-expression of 2B4 (CD244) and CD160 delineates a subpopulation of human CD8+ T cells with a potent CD160-mediated cytolytic effector function. European Journal of Immunology, 2006, 36, 2359-2366.	1.6	55
153	SC5 mAb Represents a Unique Tool for the Detection of Extracellular Vimentin as a Specific Marker of Sèzary Cells. Journal of Immunology, 2006, 176, 652-659.	0.4	63
154	CD molecules 2005: human cell differentiation molecules. Blood, 2005, 106, 3123-3126.	0.6	110
155	Circulating Natural Killer Lymphocytes Are Potential Cytotoxic Effectors Against Autologous Malignant Cells in Sezary Syndrome Patients. Journal of Investigative Dermatology, 2005, 125, 1273-1278.	0.3	37
156	The CD160+ CD8high cytotoxic T cell subset correlates with response to HAART in HIV-1+ patients. Cellular Immunology, 2005, 237, 96-105.	1.4	28
157	T-cell: Section report. Cellular Immunology, 2005, 236, 3-5.	1.4	1
158	SC3 monoclonal antibody defines a novel specific human B-cell surface antigen differentially expressed on B-cell leukaemias and lymphomas and involved in the proliferation of normal and malignant B lymphocytes. Cellular Immunology, 2005, 236, 92-100.	1.4	0
159	HLA Class I/NK Cell Receptor Interaction in Early Human Decidua basalis: Possible Functional Consequences. , 2005, 89, 72-83.		20
160	Soluble CD100 functions on human monocytes and immature dendritic cells require plexin C1 and plexin B1, respectively. International Immunology, 2005, 17, 439-447.	1.8	84
161	Cutting Edge: Engagement of CD160 by its HLA-C Physiological Ligand Triggers a Unique Cytokine Profile Secretion in the Cytotoxic Peripheral Blood NK Cell Subset. Journal of Immunology, 2004, 173, 5349-5354.	0.4	105
162	CD158k/KIR3DL2 Is a New Phenotypic Marker of Sezary Cells: Relevance for the Diagnosis and Follow-Up of Sezary Syndrome. Journal of Investigative Dermatology, 2004, 122, 820-823.	0.3	135

#	Article	IF	Citations
163	Evaluation of the Potential Role of Cytokines in Toxic Epidermal Necrolysis. Journal of Investigative Dermatology, 2004, 123, 850-855.	0.3	152
164	Sezary Syndrome Cells Unlike Normal Circulating T Lymphocytes Fail to Migrate Following Engagement of NT1 Receptor. Journal of Investigative Dermatology, 2004, 122, 111-118.	0.3	16
165	Toxic epidermal necrolysis: Effector cells are drug-specific cytotoxic T cells. Journal of Allergy and Clinical Immunology, 2004, 114, 1209-1215.	1.5	353
166	Semaphorin CD100 from Activated T Lymphocytes Induces Process Extension Collapse in Oligodendrocytes and Death of Immature Neural Cells. Journal of Immunology, 2004, 172, 1246-1255.	0.4	97
167	Killer cell immunoglobulin-like receptor expression delineatesin situSÃ©zary syndrome lymphocytes. Journal of Pathology, 2003, 199, 77-83.	2.1	47
168	Functional and molecular characterization of a KIR3DL2/p140 expressing tumor-specific cytotoxic T lymphocyte clone infiltrating a human lung carcinoma. Oncogene, 2003, 22, 7192-7198.	2.6	22
169	Immunopathogenesis of cutaneous T-cell lymphomas. Hematology/Oncology Clinics of North America, 2003, 17, 1313-1317.	0.9	7
170	Polymorphic expression of CD158k/p140/KIR3DL2 in Sèzary patients. Blood, 2003, 101, 1203-1203.	0.6	9
171	Structure and Function of the Immune Semaphorin CD100/SEMA4D. Critical Reviews in Immunology, 2003, 23, 65-81.	1.0	35
172	Engagement of CD160 receptor by HLA-C is a triggering mechanism used by circulating natural killer (NK) cells to mediate cytotoxicity. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 16963-16968.	3.3	128
173	CD Antigens 2001. Modern Pathology, 2002, 15, 71-76.	2.9	7
174	BY55/CD160 acts as a coâ€receptor in TCR signal transduction of a human circulating cytotoxic effector T lymphocyte subset lacking CD28 expression. International Immunology, 2002, 14, 445-451.	1.8	88
175	Engagement of ILT2/CD85j in Sèzary syndrome cells inhibits their CD3/TCR signaling. Blood, 2002, 100, 1019-1025.	0.6	31
176	Drug Specific Cytotoxic T-Cells in the Skin Lesions of a Patient with Toxic Epidermal Necrolysis. Journal of Investigative Dermatology, 2002, 118, 728-733.	0.3	260
177	CD4+ cutaneous T-cell lymphoma cells express the p140â€killer cell immunoglobulin-like receptor. Blood, 2001, 97, 1388-1391.	0.6	119
178	Increased Expression of a Novel Early Activation Surface Membrane Receptor in Cutaneous T Cell Lymphoma Cells. Journal of Investigative Dermatology, 2001, 116, 731-738.	0.3	27
179	Functional Characterization of Neurotensin Receptors in Human Cutaneous T Cell Lymphoma Malignant Lymphocytes. Journal of Investigative Dermatology, 2001, 117, 687-693.	0.3	18
180	CD antigens 2001. European Journal of Immunology, 2001, 31, 2841-2847.	1.6	3

#	Article	IF	Citations
181	Biological Activity of Soluble CD100. II. Soluble CD100, Similarly to H-SemaIII, Inhibits Immune Cell Migration. Journal of Immunology, 2001, 166, 4348-4354.	0.4	154
182	Multiple co-stimulatory signals are required for triggering proliferation of T cells from human secondary lymphoid tissue. International Immunology, 2001, 13, 441-450.	1.8	7
183	Biological Activity of Soluble CD100. I. The Extracellular Region of CD100 Is Released from the Surface of T Lymphocytes by Regulated Proteolysis. Journal of Immunology, 2001, 166, 4341-4347.	0.4	130
184	CD antigens 2001. International Immunology, 2001, 13, 1095-1098.	1.8	3
185	Triggering CD101 molecule on human cutaneous dendritic cells inhibits T cell proliferation via IL-10 production. European Journal of Immunology, 2000, 30, 3132-3139.	1.6	35
186	Functional Inhibitory Receptors Expressed by a Cutaneous T Cell Lymphoma-Specific Cytolytic Clonal T Cell Population. Journal of Investigative Dermatology, 2000, 115, 994-999.	0.3	9
187	Cutaneous T Cell Lymphoma Reactive CD4+ Cytotoxic T Lymphocyte Clones Display a Th1 Cytokine Profile and Use a Fas-Independent Pathway for Specific Tumor Cell Lysis. Journal of Investigative Dermatology, 2000, 115, 74-80.	0.3	80
188	No Modulation of Circulating Natural Killer Cell and Natural Killer Receptor Bearing Memory T Cell Subsets in Patients with Atopic Dermatitis. Journal of Investigative Dermatology, 2000, 115, 1160-1162.	0.3	4
189	Functional characterization of an IL-7â€“dependent CD4+CD8Î±Î±+ Th3-type malignant cell line derived from a patient with a cutaneous T-cell lymphoma. Blood, 2000, 96, 1056-1063.	0.6	29
190	Cutting Edge: Soluble HLA-G1 Triggers CD95/CD95 Ligand-Mediated Apoptosis in Activated CD8+ Cells by Interacting with CD8. Journal of Immunology, 2000, 164, 6100-6104.	0.4	422
191	Switch in the protein tyrosine phosphatase associated with human CD100 semaphorin at terminal B-cell differentiation stage. Blood, 2000, 95, 965-972.	0.6	36
192	Functional characterization of an IL-7â€“dependent CD4+CD8Î±Î±+ Th3-type malignant cell line derived from a patient with a cutaneous T-cell lymphoma. Blood, 2000, 96, 1056-1063.	0.6	3
193	Production and characterization of 22 monoclonal antibodies directed against S 20499, a new potent 5-HT1A chiral agonist: influence of the hapten structure on specificity and stereorecognition. Pharmaceutical Research, 1999, 16, 725-735.	1.7	1
194	Soluble CD14 acts as a negative regulator of human Tâ€‰cell activation and function. European Journal of Immunology, 1999, 29, 265-276.	1.6	111
195	Do Primary Cutaneous Non-T Non-B CD4+CD56+ Lymphomas Belong to the Myelo-Monocytic Lineage?. Journal of Investigative Dermatology, 1998, 111, 1242-1244.	0.3	26
196	T Cell Receptor (TCR) Interacting Molecule (TRIM), A Novel Disulfide-linked Dimer Associated with the TCRâ€“CD3â€“Î¶ Complex, Recruits Intracellular Signaling Proteins to the Plasma Membrane. Journal of Experimental Medicine, 1998, 188, 561-575.	4.2	121
197	Isolation of Tumor-Specific Cytotoxic CD4+ and CD4+CD8dim+ T-Cell Clones Infiltrating a Cutaneous T-Cell Lymphoma. Blood, 1998, 91, 4331-4341.	0.6	128
198	Isolation of Tumor-Specific Cytotoxic CD4+ and CD4+CD8dim+ T-Cell Clones Infiltrating a Cutaneous T-Cell Lymphoma. Blood, 1998, 91, 4331-4341.	0.6	13

#	Article	IF	Citations
199	The Human Semaphorin-like Leukocyte Cell Surface Molecule CD100 Associates with a Serine Kinase Activity. Journal of Biological Chemistry, 1997, 272, 23515-23520.	1.6	54
200	Interferon-Î³ rescues HLA class Ia cell surface expression in term villous trophoblast cells by inducing synthesis of TAP proteins. European Journal of Immunology, 1997, 27, 45-54.	1.6	46
201	Endothelial cells in chorionic fetal vessels of first trimester placenta express HLA-G. European Journal of Immunology, 1997, 27, 3380-3388.	1.6	152
202	Functional Role of CD101 on Skin Dendritic Cells. Advances in Experimental Medicine and Biology, 1997, 417, 227-232.	0.8	0
203	Enhanced CD3 Monoclonal Antibody Induced Proliferation of Colonic Mucosal T Lymphocytes in Crohn's Disease Patients Free of Corticosteroid or Immunosuppressor Treatment. Clinical Immunology and Immunopathology, 1996, 79, 20-24.	2.1	2
204	Activation signals are delivered through two distinct epitopes of CD100, a unique 150 kDa human lymphocyte surface structure previously defined by BB18 mAb. International Immunology, 1995, 7, 1-8.	1.8	61
205	Differential proliferative responses in subsets of human CD28+cells delineated by BB27 mAb. International Immunology, 1994, 6, 423-430.	1.8	19
206	A Monoclonal Antibody to the Hodgkin's Disease-Associated Antigen CD30 Induces Activation and Long-Term Growth of Human Autoreactive Î³Î´ T Cell Clone. Cellular Immunology, 1994, 156, 230-239.	1.4	14
207	Identification of a novel functional 85-kD glycoprotein restricted to long-term dividing human lymphocytic lines. Human Immunology, 1993, 37, 31-38.	1.2	3
208	TCR Î³Î´ Bearing T Lymphocytes Infiltrating Human Primary Cutaneous Melanomas. Journal of Investigative Dermatology, 1992, 98, 369-374.	0.3	45
209	The CD39 molecule defines distinct cytotoxic subsets within alloactivated human CD8-positive cells. European Journal of Immunology, 1992, 22, 2681-2685.	1.6	30
210	Modulation of allogenic reaction by ticlopidine treatment. International Journal of Immunopharmacology, 1991, 13, 101-105.	1.1	0
211	Proliferation of resting lymphocytes is induced by triggering T cells through an epitope common to the three CD18/CD11 leukocyte adhesion molecules. Cellular Immunology, 1991, 136, 519-524.	1.4	18
212	Activation of the CD3/T cell receptor (TcR) complex or of protein kinase C potentiate adenylyl cyclase stimulation in a tumoral T cell line: involvement of two distinct intracellular pathways. European Journal of Immunology, 1991, 21, 2877-2882.	1.6	22
213	Identification of CD3 Associated T Cell Receptor as a Diagnostic Tool in T Cell Acute Lymphoblastic Lymphoma or Leukemia. Leukemia and Lymphoma, 1991, 4, 187-192.	0.6	1
214	Immunodeficiency after Bone Marrow Transplantation can be associated with Autoreactive T-Cell Receptor gammaomega-bearing Lymphocytes. Immunological Reviews, 1990, 116, 5-13.	2.8	11
215	Correlation between T cell receptor Î³Î´ isotypic forms and cytotoxic activity: Analysis with human T cell clones and lines. Cellular Immunology, 1990, 125, 315-325.	1.4	12
216	Selective induction of autocytotoxic activity through the CD3 molecule. European Journal of Immunology, 1990, 20, 2615-2619.	1.6	10

#	Article	IF	Citations
217	Detection of a T cell receptor Î´ chain with an anti-TCR Î± chain serum. Clinical Immunology and Immunopathology, 1990, 55, 56-66.	2.1	0
218	Rearranging sequence located in the intron of the human T cell receptor Î³ chain gene constant region. European Journal of Immunology, 1989, 19, 637-642.	1.6	3
219	Immunoactive products of human placenta. II. Direct inhibition of non-MHC restricted cytolytic activity of human CD3 alpha-beta but not CD3 gamma-delta expressing T cell clones. Journal of Reproductive Immunology, 1989, 16, 137-150.	0.8	17
220	Molecular and Functional Characterization of Human T-Cell Clones Expressing TCR-Î³Î´ Antigen Receptor. , 1989, , 554-554.		1
221	CD4 cytotoxic T lymphocyte differentiation. Biochimie, 1988, 70, 937-941.	1.3	0
222	Nucleotide sequence of a cDNA corresponding to a new human variable region of a functionally rearranged T cell receptor gamma chain. Nucleic Acids Research, 1987, 15, 10059-10059.	6.5	9
223	In vitro allostimulation of peripheral blood mononuclear cells generates autologous reactive T lymphocytes: Analysis at the clonal level. Human Immunology, 1986, 17, 54-60.	1.2	2
224	What is a T-cell clone? Effect of rIFN on T-cell clone function and T-cell receptor gene rearrangement. Human Immunology, 1986, 17, 214-223.	1.2	10
225	Allospecific proliferative human T-cell clones acquire the cytotoxic effector function after three months in culture, in IL-2 conditioned medium. Human Immunology, 1986, 17, 30-36.	1.2	6
226	Human T lymphocyte clones with killer or natural killer activity. Journal of Immunological Methods, 1986, 90, 215-219.	0.6	3
227	Interferon: a cytotoxic T lymphocyte differentiation signal. European Journal of Immunology, 1986, 16, 767-770.	1.6	113
228	The human T-cell receptor. Journal of Clinical Immunology, 1985, 5, 141-157.	2.0	39
229	Production and characterization of antibody probes directed at constant regions of the Î± and Î² subunit of the human T cell receptor. European Journal of Immunology, 1985, 15, 821-827.	1.6	28
230	T3-Ti receptor triggering of T8+ suppressor T cells leads to unresponsiveness to interleukin-2. Nature, 1984, 311, 565-567.	13.7	49
231	Clonotypic Surface Structure on Human T Lymphocytes: Functional and Biochemical Analysis of the Antigen Receptor Complex. Immunological Reviews, 1984, 81, 95-130.	2.8	82
232	Differential reactivity of human lymphocytes allosensitized in vitro in hormonally defined medium or medium supplemented with plasma. Cellular Immunology, 1983, 81, 441-446.	1.4	2
233	Regulation of the human allogeneic proliferative response in vitro. Immunogenetics, 1981, 14, 107-116.	1.2	3
234	Regulation of the human allogeneic proliferative response in vitro. Immunogenetics, 1981, 14, 117-127.	1.2	7